greeksoup/ stock research
Stock research / United States / Funds / Rosalind Advisors, Inc.

Rosalind Advisors, Inc.

CIK 1622627 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Rosalind Advisors, Inc. reported 29 US-listed holdings worth $266.2 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Delcath Sys Inc. (15.6%), Fennec Pharmaceuticals Inc. (12.9%) and Xeris Biopharma Holdings Inc. (8.7%). Against the quarter before, it opened 3 positions, added to 7, trimmed 11 and sold out of 6.

Reported holdings$266.2M+9.1% on Q1 2026
Positions29-3 on Q1 2026
The largest ten74.9%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
Added toHeldTrimmed
DCTH15.6%FENC12.9%XERS8.7%SVRA7.4%VSTM5.7%XFOR5.6%EYPT5.3%HELP4.9%VOR4.5%PCVX4.4%MDWD4.1%CLDX2.8%BCRX2.7%15 more13.4%

The 14 largest of its 29 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $150.7 million in 29 positions$151MQ3 24Q4 2024: $185.7 million in 28 positions$186MQ4 24Q1 2025: $205.2 million in 31 positions$205MQ1 25Q2 2025: $206.6 million in 29 positions$207MQ2 25Q3 2025: $283.0 million in 29 positions$283MQ3 25Q4 2025: $274.5 million in 29 positions$274MQ4 25Q1 2026: $244.1 million in 32 positions$244MQ1 26Q2 2026: $266.2 million in 29 positions$266MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned +58.6% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.

Its reported holdingsThe S&P 500
100120140160Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Its holdings +58.6%S&P 500 +30.2%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Opened 3Added 7Held 8Trimmed 11Sold out 6
Opened: 3Added: 7Held: 8Trimmed: 11Sold out: 6

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 3

  1. Abivax SA ABVX$2.8 million
  2. Spruce Biosciences Inc. SPRB$1.1 million
  3. Pepgen Inc. PEPG$630,000

Added to 7

  1. Verastem Inc. VSTM+1.8 million shares · +86%
  2. Fennec Pharmaceuticals Inc. FENC+279,800 shares · +10%
  3. Cybin Inc. HELP+425,000 shares · +28%
  4. Talphera Inc. TLPH+1.8 million shares · +54%
  5. Regentis Biomaterials Ltd RGNT+450,175 shares · +179%
  6. Neuraxis Inc. NRXS+221,917 shares · +78%
  7. Biofrontera Inc. BFRI+111,647 shares · +10%

Trimmed 11

  1. Vaxcyte Inc. PCVX-90,000 shares · -31%
  2. Celldex Therapeutics Inc. CLDX-130,000 shares · -39%
  3. Xeris Biopharma Holdings Inc. XERS-322,719 shares · -10%
  4. Biocryst Pharmaceuticals Inc. BCRX-201,553 shares · -22%
  5. Onkure Therapeutics Inc OKUR-293,763 shares · -66%
  6. Polypid Ltd PYPD-208,471 shares · -35%
  7. Vor Biopharma Inc. VOR-51,400 shares · -7%
  8. Eyepoint Pharmaceuticals Inc. EYPT-48,507 shares · -5%

and 3 more in the table below

Sold out of 6

  1. CG Oncology Inc. CGON$6.8 million last quarter
  2. Viridian Therapeutics Inc. VRDN$4.9 million last quarter
  3. Definium Therapeutics Inc. DFTX$2.4 million last quarter
  4. Lipocine Inc. New LPCN$1.8 million last quarter
  5. Avalo Therapeutics Inc. AVTX$1.1 million last quarter
  6. Annexon Inc. ANNX$1.1 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Delcath Sys Inc. DCTH3.3M$41.6 million15.61%no change
Fennec Pharmaceuticals Inc. FENC3.2M$34.3 million12.87%+279.8K
Xeris Biopharma Holdings Inc. XERS2.9M$23.0 million8.65%-322.7K
Savara Inc. SVRA3.2M$19.6 million7.35%-25.6K
Verastem Inc. VSTM4.0M$15.2 million5.72%+1.8M
X4 Pharmaceuticals Inc. XFOR3.2M$15.0 million5.64%no change
Eyepoint Pharmaceuticals Inc. EYPT988.2K$14.1 million5.31%-48.5K
Cybin Inc. HELP2.0M$12.9 million4.86%+425.0K
Vor Biopharma Inc. VOR648.6K$11.9 million4.49%-51.4K
Vaxcyte Inc. PCVX200.0K$11.6 million4.37%-90.0K
Mediwound Ltd MDWD749.1K$11.0 million4.14%no change
Celldex Therapeutics Inc. CLDX200.0K$7.4 million2.80%-130.0K
Biocryst Pharmaceuticals Inc. BCRX721.5K$7.2 million2.71%-201.6K
Profound Med Corp. Com New PROF828.1K$5.5 million2.07%no change
Talphera Inc. TLPH5.2M$5.3 million2.00%+1.8M
Atea Pharmaceuticals Inc. AVIR1.1M$5.0 million1.87%-101.3K
Myomo Inc. MYO3.6M$3.8 million1.42%-209.4K
Ovid Therapeutics Inc. OVID1.1M$3.0 million1.12%no change
Neuraxis Inc. NRXS508.1K$3.0 million1.12%+221.9K
Abivax SA ABVX20.9K$2.8 million1.04%new
Inspiremd Inc. NSPR3.9M$2.7 million1.03%no change
Regentis Biomaterials Ltd RGNT701.7K$2.5 million0.93%+450.2K
Polypid Ltd PYPD389.5K$2.0 million0.74%-208.5K
Biofrontera Inc. BFRI1.3M$1.2 million0.45%+111.6K
Kura Oncology Inc. KURA100.0K$1.1 million0.41%no change
Spruce Biosciences Inc. SPRB20.0K$1.1 million0.41%new
Aquestive Therapeutics Inc. AQST250.0K$1.0 million0.39%no change
Onkure Therapeutics Inc OKUR150.0K$684,0000.26%-293.8K
Pepgen Inc. PEPG350.0K$630,0000.24%new
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 6 it sold out of are in the box above.

Options it reported

CompanyOptionShares under the optionsValue of those shares
Sellas Life Sciences Group IPuts568.7K$2.3 million
CG Oncology Inc.Calls31.0K$375,100
Eyepoint Pharmaceuticals Inc.Calls50.3K$130,780
iShares TrustPuts500.0K$110,000
SPDR Ser TrustPuts140.6K$35,150
Tenax Therapeutics Inc.Puts6.2K$13,950

6 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.